You Asked: How Worrisome is the Boxed Warning for the New Postpartum Depression Medication?
The package insert advises patients to avoid driving and other potentially hazardous activities after taking zuranolone.
The package insert advises patients to avoid driving and other potentially hazardous activities after taking zuranolone.
A new study from Hantsoo and colleagues asks whether SRI treatment affects the levels of neuroactive steroids modulating GABA-A receptors.
Childbirth-related PTSD is relatively common; routine screening with a survey of PTSD symptoms may identify women in need of specific PTSD interventions.
The FDA approves zuranolone, a new option for the treatment of PPD, a rapidly acting antidepressant with a good safety profile.
In this multicenter cohort, maternal cannabis use documented using urine drug sampling was associated with increased risk of adverse pregnancy outcomes related to placental dysfunction.
Machine learning can be used to analyze data contained within the electronic health record to accurately predict which individuals are at increased risk for postpartum depression.
A routinely administered single-item measure of sleep disturbance could identify pregnant individuals who are at risk for PPD and may benefit from depression prevention efforts.
Metabolic biomarkers in the cerebrospinal fluid may be used to identify women at high risk for postpartum depression.
The FDA approves zuranolone, a new option for the treatment of PPD, a rapidly acting antidepressant with a good safety profile.
More study is needed regarding the safety of trazodone for the treatment of insomnia during pregnancy.